Fingerprint
Dive into the research topics of 'Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically